Drug hypersensitivity reactions (DHR) are based on distinct mechanisms and are clinically
heterogeneous. Taking into account that also off‐target activities of drugs may lead to …

Controversies exist with regard to in vivo approaches to delayed immunologically mediated
adverse drug reactions, such as exanthem (maculopapular eruption), drug reaction with …

Peptide antigens bound to molecules encoded by the major histocompatibility complex
(MHC) and presented on the cell surface form the targets of T lymphocytes. This critical arm …

Background Vancomycin is a prevalent cause of the severe hypersensitivity syndrome drug
reaction with eosinophilia and systemic symptoms (DRESS), which leads to significant …

Cutaneous adverse drug reactions are unpredictable and include various different skin
conditions of varying degrees of severity. The most concerning are usually referred to as …

The HCP5 RNA gene (NCBI ID: 10866) is located centromeric of the HLA-B gene and
between the MICA and MICB genes within the major histocompatibility complex (MHC) class …

Individuals differ substantially in their response to pharmacological treatment. Personalized
medicine aspires to embrace these inter-individual differences and customize therapy by …

Drug hypersensitivity such as severe cutaneous adverse reactions (SCAR), including
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), could be life …

Adverse drug reactions (ADRs) are a common cause of hospital admissions (up to 19%),
with the majority of cases due to off‐target predictable drug effects (type A reactions) …

Some patients prescribed flucloxacillin (~ 0.01%) develop drug‐induced liver injury (DILI).
HLA‐B* 57: 01 is an established genetic risk factor for flucloxacillin DILI. To consolidate this …